Gossamer Bio, Inc. (GOSS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Gossamer Bio, Inc. reported revenue of $48.47M, down 57.7% from the prior year. The company ran a net loss, with a net margin of -351.5%. It held $172.25M in total assets against $295.01M in total liabilities.
Key ratios (FY2025)
-352.2%
Operating margin
-351.5%
Net margin
-57.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.47M | $114.70M | $0 | $0 | — | — | — | — | — | — |
| Operating Income | -$170.73M | -$59.92M | -$183.76M | -$218.59M | -$216.12M | -$233.96M | -$186.14M | -$148.99M | -$6.65M | — |
| Net Income | -$170.37M | -$56.53M | -$179.82M | -$229.38M | -$234.00M | -$243.36M | -$180.31M | -$146.97M | -$6.77M | — |
| EPS (Diluted) | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 | $-3.55 | $-3.29 | — | — | — |
| Total Assets | $172.25M | $315.29M | $311.92M | $272.45M | $343.66M | $539.43M | $426.60M | $239.42M | — | — |
| Total Liabilities | $295.01M | $285.80M | $249.15M | $260.37M | $222.19M | $218.75M | $74.12M | $21.12M | — | — |
| Shareholders' Equity | -$122.76M | $29.49M | $62.77M | $12.08M | $121.46M | $320.68M | $352.49M | -$120.07M | -$6.86M | -$123.0K |
| Cash & Equivalents | $37.73M | $46.07M | $32.11M | $111.97M | $183.40M | $486.06M | $135.03M | $105.22M | — | — |
| Operating Cash Flow | -$171.27M | -$3.47M | -$159.16M | -$187.03M | -$188.89M | -$176.36M | -$144.83M | -$51.04M | -$5.75M | — |
| Capital Expenditures | $79.0K | $0 | $0 | $410.0K | $1.55M | $1.50M | $2.97M | $3.49M | — | — |
| Shares Outstanding | 233.68M | 226.60M | 225.41M | 94.42M | 75.75M | 73.87M | 61.64M | 8.05M | — | — |